Keyword Index to Volume 12

Abanoquil Suppl 1 S37 Cardiovascular disease Drug development Fibrosis 111 Acquired curvature 289 Suppl 4 S147 Suppl 4 S158 Forskolin Suppl 1 S41 Adrenalin 312 Cardiovascular risk Drug therapy Suppl 4 Functional antagonism Adrenergic receptors Suppl 4 S6 S59 Suppl 4 S39 Suppl 4 S34 Cavernosal expandabil- Duplex ultrasound 59 Adverse events Suppl 4 ity 328 Gene therapy Suppl 4 S53 Central nervous system Ef®cacy 97 S163 Age 143 Suppl 1 S13, Suppl 4 Glans penis 195 Electromotive drug de- 0 0 Alcoholism 47 S67 livery Suppl 4 S86 3 ,5 -cyclic-GMP phos- Alpha-adrenergic ago- cGMP Suppl 4 S34 Engorgement 235 phodiesterase inhibi- nist 59 cGMP-dependent kinase eNOS 213 tors 177 Alpha adrenergic an- I157 EP peptides 255 Gonadotropin releasing tagonist Suppl 1 S26 Clinical diagnosis Suppl EP receptor 107 hormone 269 Alpha adrenergic recep- 4 S119 Epidemiologic methods Growth hormone (GH) tor Suppl 1 S20, Clitoris 111, 235 197 releasing peptides 255 Suppl 1 S41, Suppl 1 CNS pharmacology Epidemiology 305 Haemoglobin 213 S48 Suppl 4 S26, Suppl 4 Erectile dysfunction 23, Helicine arterioles 33 Alpha adrenoceptors S163 41, 47, 83, 97, 103, High-¯ow priapism Suppl 1 S5 Colchicine 169 107, 143, 147, 165, Suppl 4 S133 Alpha-1 adrenoceptor Collagen Suppl 4 S39 191, 197, 223, 263, Histamine antagonist 59 antagonist Suppl 1 S37 Collagen disease mar- 273, 279, 279, 305, HLA antigens Suppl 4 Alpha-adrenoceptor kers 302 334, Suppl 1 S20, S127 pharmacology Suppl Color Doppler ultraso- Suppl 1 S37, Suppl 1 Hypercholesterolemia 1S13 nography 263 S41, Suppl 1 S48, 334 Alpha blocker Suppl 1 Color Doppler ultra- Suppl 1 S70, Suppl 1 Hyperprolactinemia 23 S75 sound 125 S75, Suppl 4 S12, Hypertension 41 Alpha-2 blockade Suppl Co-morbidities Suppl 4 Suppl 4 S26, Suppl 4 Hypogonadism 269 1S64 S53 S34, Suppl 4 S39, Alprostadil 195 Compliance 223 Suppl 4 S47, Suppl 4 Alprostadil alfadex 205 Corporal myocyte Suppl Immunogenetics Suppl S53, Suppl 4 S62, 4 S127 Androgens Suppl 4 S112 4S15 Suppl 4 S80, Suppl 4 Anosmia 269 Corporalsmoothmuscle9 Impotence 19, 33, 125, S91, Suppl 4 S101, 137, 157, 177, 197, Antibiotic therapy 285 Corporal veno-occlusion Suppl 4 S112, Suppl 4 Apomorphine 91, 235, 315 205, 273, 315, 334, S119, Suppl 4 S122, Suppl 4 S6, Suppl 4 Suppl 4 S67 Corpus cavernosum 107, Suppl 4 S140, Suppl 4 Arteriogenic 19 157, Suppl 1 S20, S74 S147, Suppl 4 S158, Incontinence 279 Arthroplasty 143 Suppl 1 S41, Suppl 1 Suppl 4 S163 Atherosclerosis 111 S48, Suppl 4 S39 Infection 285, Suppl 4 Erectile function 91 S108 Audiovisual sexual sti- Cryptorchidism 269 Erectile function/dys- mulation 83 Injectable pharmacother- Delequamine Suppl1S64 function 328 apy Suppl 4 S91 Autonomic and somatic Erectile physiology 315, mechanisms Suppl 4 Depression 47, Suppl 4 International Index of S6 Suppl 4 S59 Erectile Function S26 Erectile tissue mechan- Axial buckling test 205 Depressive symptoms Suppl 4 S86 Suppl 4 S147 ical properties 328 Intracavernosal treat- Erection 9, 247, Suppl 4 Biomechanicalmodel328 Diabetes mellitus 41, ment Suppl 1 S81 S67 Biomedical engineering 103 Intracorporeal pressure Etiology Suppl 4 S127 315 Diagnosis 83, 247, Suppl 137 External anal sphincter Blood ¯ow 53, 235 4S12 Ischaemic heart disease 279 Bulbocavernosus mus- Diagnostic pharmaco- 41 cle 279 erection 33 Ischemia 111 Bulbocavernosus re¯ex Disease susceptibility Female 53 103 302 Female sexual arousal K channel gene therapy Dopaminergic Suppl 4 disorder Suppl 4 S152 Suppl 4 S15 cAMP 9, 107, Suppl 1 S67 Female sexual function KATP channel Suppl 4 S41, Suppl 4 S34, Drug delivery systems and dysfunction S15 Suppl 4 S39 Suppl 4 S158 Suppl 4 S152 KCa channel Suppl 4 S15 Keyword index

347 Large-conductance KCa Penile ®brosis 153 Prolactin 23 SPA 229 channels 9 Penile fracture 125, 273 Prolonged erection 312 Speci®c therapy Suppl 4 Laser Doppler 53 Penile implants Suppl 4 Prostaglandin E1 195, S12 Low-¯ow priapism S101, Suppl 4 S108, 205, Suppl 1 S26 Spectrophotometry 247 Suppl 4 S133 Suppl 4 S122 Prosthesis 285 Sperm 229 Penile induration 117, Psychiatric factors 47 Stripping 299 Magnetic coil 137 153 Psychogenic 191 Study design Suppl 4 Magnetic stimulator 137 Penile prosthesis 147, Psychopathology 47 S53 Maxi-K channel 9 153, 195 Psychosocial disorders Surgery 143, Suppl 4 Medical treatment 169 Penile re¯exes 23 Suppl 4 S144 S47, Suppl 4 S101, MHC Class II Suppl 4 Penile rigidity 205 Pudendal artery 183 Suppl 4 S108, Suppl 4 S127 Penile straightening 147 Pudendal nerve con- S140 Misoprostol 107 Penile tumescence 137 duction 103 Surgical treatment Motility 229 Penile vascular resis- Suppl 4 S122 MSH Suppl 4 S74 tance 183 Quality of life measures Sympathetic nerves MUSE 195 Penis 183, 247, 289, 299, Suppl 4 S144 Suppl 1 S5 Nerve stimulation 53 334, Suppl 4 S91 Questionnaire 165, Nesbit 289 Peripheral vascular dis- Suppl 4 S6 TGF-b 169 Questionnaires Suppl 4 Nitric oxide 213, 334 ease 41 TGF-b1 Suppl 4 S39 Nitric oxide synthase Peyronie's disease 147, S144 Therapeutic evaluation 169, 263, 289, 299, 334 Rabbit 334 Suppl 4 S53 302, Suppl 4 S86, nNOS 213 Radical prostatectomy Tissue hypoxia Suppl 4 Suppl 4 S108, Suppl 4 NO/cGMP pathway 165 S133 S122, 312 Suppl 4 S62 Rat 53, 91, 213, 285 Topical therapy Suppl 4 PGE1 107, Suppl 1 S41 Non-steroidal anti-an- Relaxation 9 S80 PGE Suppl 4 S39 drogen 59 1 Review Suppl 4 S80, TP receptor 107 Pharmacocavernosome- NoradrenalineSuppl1S5 Suppl 4 S101, Suppl 4 Transmembrane poten- try 83 S112, Suppl 4 S122, tial Suppl 4 S15 Oral agents Suppl 1 S75 Pharmacologic therapy Suppl 4 S140 Transurethral alprosta- Oral treatment Suppl 1 205 dil 97 S81 Pharmacotherapy Suppl Safety 97 Trauma 273 Oxygen 19 4 S47, Suppl 4 S62, Trazodone 223 Oxytocin 255 Selection 205 Suppl 4 S86, Suppl Self-injection therapy Treatment 312 Paraventricular nucleus 4 S112, Suppl 4 191 Treatment algorithm of the hypothalamus S158 Sex behavior Suppl 4 Suppl 4 S119 rat 255 Physiology Suppl 1 S81 S74 Treatment of ED 191 Penile anatomy Suppl 4 Placebo-controlled Sexual activity 143 Tumescence 195 S47 Suppl 4 S53 Sexual behavior Suppl 1 Tunica albuginea 273 Penile blood ¯ow Suppl Population studies 197 S13 4S133 Post-marketing safety Sexual function 197, Vagina 235 Penile blood ¯ow study Suppl 4 S62 289 Vascular endothelial 165 Potassium channels Sexual relationships growth factor 334 Penile curvature 117, Suppl 4 S34 Suppl 4 S144 Vascular smooth muscle 273 Power Doppler 33 Sickle cell anemia 59 107, Suppl 1 S20, Penile detumescence Premature ejaculation Sickle-cell disease Suppl 1 S41, Suppl 1 Suppl 1 S5 Suppl 4 S80 Suppl 4 S133 S48, Suppl 4 S34, Penile disorders Suppl 4 Pre-synaptic Suppl 1 Sildena®l 165, 177, 229, Suppl 4 S39, Suppl 4 S127 S20 Suppl 1 S26 S59 Penile erection 177, 213, Prevalence 41, Suppl 4 Smooth muscle 111 Vein grafting 299 255, Suppl 1 S5, S6 Smooth muscle tone Viability 229 Suppl 1 S13, Suppl 1 Priapism 59 Suppl 4 S15 VIP Suppl 1 S26 S75, Suppl 1 S81, Procedure related dis- Soluble guanylate cy- Suppl 4 S74 tress 83 clase 157 Yohimbine Suppl 1 S70

International Journal of Impotence Research